| NCT04588922 | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies | RECRUITING | PHASE1, PHASE2 | 2021-05-10 | 2025-12-31 | 2025-12-30 |
| NCT04229979 | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-02-08 | 2026-12 | 2025-12 |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | COMPLETED | PHASE1, PHASE2 | 2019-09-30 | 2022-10-27 | 2022-07-05 |
| NCT01827137 | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | COMPLETED | PHASE1, PHASE2 | 2013-04 | 2017-11-06 | 2016-12-07 |
| NCT01266083 | WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) | COMPLETED | PHASE2 | 2011-01-14 | 2016-09-30 | 2016-09-30 |
| NCT01265433 | Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | COMPLETED | PHASE2 | 2010-12-21 | 2017-07-25 | 2016-11-30 |